FDA approves new drug to treat rare lung disease that primarily affects women

["FDA Office of Women's Health" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA approves new drug to treat rare lung disease that primarily affects women

	May 2015 www.fda.gov/womens FDA approves Rapamune to treat LAM, a very rare lung disease On May 28, 2015, the U.S. Food and Drug Administration approved Rapamune (sirolimus), to treat lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that primarily affects women of childbearing age. This is the first drug approved to treat the disease. LAM is characterized by an abnormal growth of smooth muscle cells that invade lung tissues, including the airways, and blood/lymph vessels that cause destruction of the lung, resulting in airflow obstruction, and limiting the delivery of oxygen to the body. Read more Please share this update with your network, members, constituents, and community. FDA Office of Women’s Health 10903 New Hampshire Avenue WO32 - Room 2333 Silver Spring, MD 20993-0002 301-796-9440

---

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420